High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS

@article{Romaniuk2018HighCA,
  title={High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS},
  author={Wioletta Romaniuk and Lukasz Bolkun and Joanna Kalita and Marzenna Galar and Malgorzata Bernatowicz and Halina Ostrowska and Janusz Kloczko},
  journal={Annals of Hematology},
  year={2018},
  pages={1-9}
}
Proteasome inhibitors (PIs) such as bortezomib constitute an important part of the modern standard therapy for multiple myeloma (MM). In this study, we set out to assess whether proteasome concentration and chymotrypsin-like (ChT-L) activity could serve as potential biomarkers defining the likelihood of response to treatment with bortezomib, in order to… CONTINUE READING